Ori Biotech selected to participate in the London Mayor’s International Business Programme

December 4, 2019, London, UK – Ori Biotech Ltd (Ori), a London- and Philadelphia-based innovator in Cell and Gene Therapy (CGT) manufacturing, has been selected to participate in the London Mayor’s International Business Programme (MIBP), which showcases some of the most innovative companies in London. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, Ori has designed a bespoke platform to specifically address the unique requirements of the new generation of personalised, living medicines. Helping to deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.

As part of MIBP, Ori will act as an ambassador for the UK advanced therapies community on international trade missions. In line with the UK Government’s Industrial Strategy, CGTs – and technologies that enable their widespread access – have significant potential as a new source of economic growth according to the Advanced Therapies Manufacturing Taskforce. It was set up to identify actions that the UK must consider taking in order to anchor manufacturing of advanced therapies and capture investments to secure the UK’s position as a world-class hub.

“We have seen rapid growth and significant clinical success with advanced therapies in recent years and the UK has been at the forefront of this research and development. The sector is moving quickly and is now at a critical point, as it prepares to commercialise and scale up manufacture of these treatments,” wrote Ian McCubbin, Chair of Medicines Manufacturing Industry Partnership in the Advanced Therapies Manufacturing Action Plan Report.1 The report stated that, “The UK is very well placed to anchor manufacturing of these potentially curative therapies in the UK and secure its position as a global hub for advanced therapies but the time to act is now. The forthcoming Industrial Strategy gives us an opportunity to take forward this report and work together to secure investments, further the science, and contribute significant benefits to the UK economy and patients in the UK and worldwide.”1

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.

For more information, contact:

Ori Biotech
Jason C. Foster, CEO
jasonfoster@oribiotech.com

Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 0891
oribiotech@optimumcomms.com

info@oribiotech.com

Oribiotech Ltd
London Biosciences Innovation Centre
2 Royal College Street
London
NW1 0NH